Osteoarthritis and Bone Disorders News

DESTIN, Fla. — Cell senescence may represent the “most exciting” development in the potential treatment of osteoporosis, according to Michael R. McClung, MD, of Australian Catholic University and the Oregon Osteoporosis Center.

In honor of Osteoporosis Awareness Month in May, advocacy organizations used social media to spread the word about the disease, including tips for patients on how to better manage their disease.

Routine, proactive therapeutic drug monitoring for patients receiving biopharmaceuticals for rheumatic and musculoskeletal diseases is not recommended, according to new points-to-consider published by EULAR.

Among the many unanswered questions about calcium pyrophosphate deposition — formerly called “pseudogout” — perhaps the most important is whether it causes osteoarthritis, a speaker said at the Congress of Clinical Rheumatology East.

DESTIN, Fla. — Understanding when to switch from one class of drugs to another is critical to maintaining bone health and preventing fractures in osteoporosis, according to data presented at the Congress of Clinical Rheumatology East.

Patients who receive tramadol for osteoarthritis demonstrate an increased risk for hip fractures, venous thromboembolism and mortality, compared with those treated with NSAIDs, according to data published in Arthritis Research and Therapy.

SAN DIEGO — Men with osteoporosis receiving daily injections of abaloparatide had greater increases in bone mineral density at the lumbar spine, total hip and femoral neck at 12 months compared with placebo, according to a speaker.

Postmenopausal women assigned denosumab have increases in mineral to matrix ratio at the cortical and cancellous bone at 2 to 3 years, but changes were not observed beyond 5 years, according to study findings.

The FDA has given 510(k) clearance for artificial intelligence software developed to support providers in the evaluation and assessment of musculoskeletal disease for older adults, according to an industry press release.

Orthofix Medical Inc. announced it received FDA pre-market approval for the AccelStim bone healing therapy class III device, which provides nonsurgical treatment for indicated fresh fractures and nonunions.